Investing.com - Financial Markets Worldwide
📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

Biomarin Pharmaceutical Inc (1BMRN)

Milan
Symbol
Exchange
Currency
BMRNNASDAQUSD
1BMRNMilanEUR
BMRNTradeGateEUR
B1MR34B3BRL
BMRNViennaEUR
Currency in EUR
Disclaimer
62.38
-0.54(-0.86%)
Closed
Fair Value
Unlock Value
Day's Range
62.3862.38
52 wk Range
61.2691.38
Prev. Close
62.38
Open
62.38
Day's Range
62.38-62.38
52 wk Range
61.26-91.38
Volume
0
Average Volume (3m)
136
1-Year Change
-
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
1BMRN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Strong Sell
Analysts Sentiment
Buy
Price Target
102.67
Upside
+49.47%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Unlock InvestingPro

Biomarin Pharmaceutical Inc News & Analysis

Show more

Biomarin Pharmaceutical Inc Company Profile

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
3082
Market
United States

Compare 1BMRN to Peers and Sector

Metrics to compare
1BMRN
Peers
Sector
Relationship
P/E Ratio
0.0x−4.8x−0.6x
PEG Ratio
0.00−0.190.00
Price/Book
0.0x2.5x2.6x
Price / LTM Sales
0.0x3.2x3.3x
Upside (Analyst Target)
0.0%52.7%44.5%
Fair Value Upside
Unlock22.3%6.0%Unlock

FAQ

What Is the Biomarin Pharma (1BMRN) Stock Price Today?

The Biomarin Pharma stock price today is 62.38

What Stock Exchange Does Biomarin Pharma Trade On?

Biomarin Pharma is listed and trades on the Milan stock exchange.

What Is the Stock Symbol for Biomarin Pharma?

The stock symbol for Biomarin Pharma is "1BMRN."

What Is the Biomarin Pharma Market Cap?

As of today, Biomarin Pharma market cap is 11.92B.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.